Contact
Print
Respiratory
PSI is a leading full-service CRO with 800+ staff in Europe (Eastern, Central, Western), the USA and Latin America.
PSI is known and respected for consistently securing fast patient enrollment into clinical trials of all sizes and levels of complexity, across a broad range of indications.
PSI has successfully performed Phase II/III studies in the following respiratory indications:
PSI employs physicians as full-time monitors and project managers, most of whom are board certified specialists, including pulmonologists, critical care specialists, and neonatologists.
PSI is known and respected for consistently securing fast patient enrollment into clinical trials of all sizes and levels of complexity, across a broad range of indications.
PSI has successfully performed Phase II/III studies in the following respiratory indications:
- Acute bronchitis
- ARDS
- COPD
- Asthma
- Adult
- Pediatric
- Cystic Fibrosis
- Lung cancer
- Neonatal RDS
- Pneumonia
- CAP
- HAP
| Respiratory Indication | # Sites |
| Acute bronchitis | 132 |
| ARDS | 62 |
| Asthma, adult | 150 |
| Asthma, pediatric | 71 |
| COPD | 120 |
| Cystic fibrosis | 30 |
| Lung cancer | 90 |
| Neonatal RDS | 25 |
| Pneumonia | 117 |
| 797 |
PSI employs physicians as full-time monitors and project managers, most of whom are board certified specialists, including pulmonologists, critical care specialists, and neonatologists.